Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sigvotatug vedotin - Seagen

Next Previous
Drug Profile

Sigvotatug vedotin - Seagen

Alternative Names: PF-08046047; SGN-B6A

Latest Information Update: 08 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Seattle Genetics
  • Developer Seagen
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 03 Jan 2025 Pfizer plans a phase III trial for Non-small cell lung cancer (Late-stage disease, Inoperable/Unresectable, Combination therapy, First-line therapy, Metastatic disease) (IV) in January 2025 (NCT06758401)
  • 21 Aug 2024 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Second-line therapy or greater, Metastatic disease, Late-stage disease) in China (IV) (NCT06549816)
  • 12 Aug 2024 Seagen plans a phase I trial for Solid tumours(Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) (IV) in August 2024 (NCT06549816)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top